Antimicrobial resistance represents a serious threat to public health in Europe and beyond. Within the last decades resistance has increased considerably in many clinically important pathogenic bacteria.
The challenge is to address this threat via a multi-disciplinary approach by developing suitable clinical management and infection prevention plans detailing how to deal with resistant bacterial infections in high prevalence settings. This topic will contribute to the implementation of the EU One Health Action Plan against Antimicrobial Resistance.
Proposals should focus on the identification of best practices, and the development and validation of interventions, infection prevention and clinical management plans for dealing with resistant bacterial infections in high prevalence settings.
The research needs to take into account the variety and capacities of local health care/nosocomial infrastructures, and the trends of resistance patterns on local, national and international level, as well as sex and/or gender differences, when relevant. Furthermore, research needs to lead to management plans that take into account commonalities as well as differences between different pathogens and resistance determinants.
The costs and benefits of the infection prevention and clinical management plans to be developed should be assessed as well as the feasibility of their implementation. Research into the practicalities and challenges to introduce such novel infection prevention and management plans is essential and their practical implementation, as pilot actions, in 2 or more European regions with high prevalence levels is strongly encouraged, while taking into account that the infection prevention and clinical management plans to be developed should be applicable for large geographical areas.
The Commission considers that proposals requesting a EU contribution of EUR 10-15 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
- Availability of tested cost effective models for prevention and treatment of bacterial infections in health care settings with high prevalence levels of resistant infections.
- Reduced spread of resistant hospital acquired infections in these settings.
- Knowledge that can be of use for other countries around the globe, including low and middle income countries, benefitting their local population and diminishing the global spread of resistant bacteria.
04 June 2020 17:00:00 Brussels time